Coversam

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Coversam

Quick Facts

Property Description
Active ingredient Perindopril and Amlodipine
Form Tablet (Oral solid dosage form)
Pharmacological class ACE inhibitor and Calcium Channel Blocker combination
Common use Lowering high blood pressure (Hypertension)
Origin Synthetic chemical compounds

What is Coversam?

Coversam is a prescription-only antihypertensive agent classified as a combination medicine used to manage chronic high blood pressure. It is a synthetic drug that combines two distinct types of cardiovascular medication into a single, convenient dosage form, making it effective for long-term therapy.

What Type of Medicine is Coversam?

Coversam is a Fixed-Dose Combination (FDC) product supplied as an oral tablet that integrates two active substances. This single-pill combination format is designed to simplify a patient's daily regimen, a significant benefit for maintaining treatment adherence. The convenience of taking one tablet instead of two separate pills helps patients stick to their prescribed regimen, a factor clinically recognized for improving long-term management of chronic conditions.

How is Coversam Composed and Classified?

Coversam contains two primary active ingredients: Perindopril and Amlodipine. The medicine is a compound agent integrating an Angiotensin-Converting Enzyme (ACE) inhibitor (Perindopril) with a Calcium Channel Blocker (CCB) (Amlodipine), placing it in the pharmacological class of ACE inhibitors with calcium channel blocking agents. This formulation is often used in a typical scenario where a patient requires two distinct antihypertensive mechanisms to achieve optimal blood pressure goals. The two components work together to provide a dual approach to blood pressure lowering, which provides a more comprehensive reduction of circulatory resistance than either substance could achieve alone.

Regulatory References

  1. ACE Inhibitor and Calcium Channel Blocker Combination Therapy (NIH)

What side effects are possible with Coversam?

Possible Side Effects and Safety Information

The safety profile of Coversam (Perindopril and Amlodipine) is defined by official regulatory documents, which classify adverse reactions by their frequency and the System-Organ Class they affect.

Frequency-Classified Adverse Reactions

The following are classified according to standard regulatory frequency bands, based on documented clinical data:

Classification Examples of Reactions
Common (ge 1/100 to <1/10) Dizziness, Headache, Somnolence, Cough, Nausea, Abdominal Pain, Fatigue, Peripheral Oedema (Ankle Swelling).
Uncommon (ge 1/1,000 to <1/100) Insomnia, Depression, Syncope, Tachycardia, Rhinitis.
Very Rare (<1/10,000) Angioedema, Hepatitis, Pancreatitis, Leukopenia, Thrombocytopenia.

Serious Adverse Reactions and Safety Constraints

The official label highlights certain rare but clinically significant events. The most serious documented risks are Angioedema (a rapid, potentially life-threatening swelling of the face, tongue, and throat) and Severe Symptomatic Hypotension (excessively low blood pressure that may lead to secondary events like myocardial infarction in susceptible patients).

Time-Related Patterns

Adverse effects such as dizziness and headache are explicitly noted as being more likely to occur at the beginning of the treatment.

Population-Specific Constraints

The medicine is not suitable for patients with severe renal impairment (Creatinine Clearance < 60 mL/min). Caution is required for use in patients with hepatic impairment. Coversam is contraindicated during the second and third trimesters of pregnancy, as stated in regulatory documents.

Overdose and Emergency Response

Overdose and When to Seek Help

The official overdose profile for Coversam (Perindopril/Amlodipine) is primarily defined by the severe cardiovascular effects resulting from excessive pharmacological action.

Property Official Regulatory Documentation
Documented Manifestations Marked systemic hypotension, excessive peripheral vasodilatation, and potentially life-threatening shock are documented as primary outcomes. Other effects include bradycardia (slow heart rate), reflex tachycardia, dizziness, confusion, and non-cardiogenic pulmonary oedema [Source: EMA SmPC, FDA].
Immediate Action Required Seek immediate medical attention. If a victim has collapsed, had a seizure, has trouble breathing, or can't be awakened, immediately call emergency services [Source: NIH, FDA].
Supportive Management No specific antidote is known for the Amlodipine component. Treatment involves symptomatic and supportive treatment, often requiring intravenous infusion of physiological saline (volume expansion) to correct hypotension. Continuous hospital monitoring of vital signs, ECG, and blood tests is required until symptoms resolve [Source: EMA SmPC, FDA].
Specific Considerations Overdose with the Perindopril component carries a risk of hyperkalaemia (high potassium), which is typically reversible upon discontinuation of the drug [Source: FDA]. The Amlodipine component is highly protein bound, and haemodialysis is unlikely to be of benefit [Source: EMA SmPC].

The drug's toxicological profile, characterized by severe hypotension and the absence of a specific counteracting agent, necessitates that regulatory authorities mandate immediate emergency medical help for any suspected overdose to manage the high risk of shock and subsequent systemic complications.

Therapeutic Uses of Coversam

What Coversam Treats: Main Uses and Benefits

Coversam is generally used to support sustained, long-term blood pressure management in adults. Its therapeutic benefits are centered on treating the underlying chronic condition and supporting the reduction of risk for severe cardiovascular consequences. The medicine is indicated for the treatment of essential hypertension and/or stable coronary artery disease in certain patients.

The therapy plays a role in managing the long-term risk associated with uncontrolled pressure, which often presents as asymptomatic pathological elevation of both systolic and diastolic pressures. When applied in addressing this systemic imbalance, Coversam may assist with managing the patient's risk profile for major vascular events and is relevant for managing the risk of stroke and myocardial infarction. It is commonly used as a first-line combination therapy or when monotherapy with a single drug may not be appropriate for managing these symptoms.

The fixed-dose format contributes to easing the overall symptom load by supporting adherence to the daily regimen. This assists with maintaining functional stability over the long term, providing support that helps ease the overall symptom burden:

“The combination is commonly used to help with the consistent, daily management relevant for chronic hypertension.”


Quick Fact: Relief for Systemic Strain

Property Description
Primary Condition Essential Hypertension (sustained high blood pressure)
Symptom Domain Systemic Imbalance (asymptomatic pressure elevation)
Key Benefit Support for Risk Management (stroke and heart attack)
Clinical Scenario Dual Therapy needed for effective long-term control

Eligibility and Restrictions for Use

The eligibility for using Coversam (Perindopril/Amlodipine) is defined by patient status, pre-existing conditions, and age, as detailed in regulatory labeling.


Absolute Contraindications

Use is prohibited for patients with a known hypersensitivity to any ingredient, other ACE inhibitors, or dihydropyridine derivatives. The medicine is contraindicated in the second and third trimesters of pregnancy, and in patients with a history of angioedema related to previous ACE inhibitor treatment.

Absolute contraindications also include severe cardiovascular states like cardiogenic shock, severe hypotension, and significant outflow tract obstructions (e.g., aortic stenosis). It must not be used concurrently with Sacubitril/Valsartan or Aliskiren in patients with diabetes or impaired kidney function.


Restrictions and Limitations

  • Age: The fixed-dose combination is not recommended for use in children and adolescents under 18 years of age, as efficacy and tolerability are not established.
  • Organ Function: Severe renal impairment (CrCl < 30 mL/min) is a contraindication. The FDC is not suitable for moderate renal impairment (CrCl 30-60 mL/min), which requires individual component titration. Use is not recommended during the first trimester of pregnancy or while breastfeeding.

What should I know about interactions with other medicines?

The official regulatory documents define the interaction profile of Coversam based on the additive effects and pharmacokinetic constraints of its two components, Perindopril and Amlodipine.

Officially Documented Interaction Restrictions

Contraindicated Combinations: The co-administration of Sacubitril/Valsartan and Intravenous Dantrolene is formally prohibited by regulatory labeling. The combination is also contraindicated with Aliskiren in patients diagnosed with diabetes mellitus or moderate-to-severe renal impairment. Additionally, certain extracorporeal treatments involving high-flux membranes are restricted.

Timing and Exposure Rules: A mandatory 36-hour separation period is required before starting Perindopril treatment after the last dose of Sacubitril/Valsartan. Furthermore, the medicine must be administered as a single daily dose before a meal, as documented evidence indicates that food reduces the bioavailability of the active Perindoprilat metabolite.

Pharmacodynamic and Metabolic Risks: The use of Potassium-Sparing Diuretics or Potassium Supplements increases the risk of hyperkalemia. Co-administration with NSAIDs may lead to renal function deterioration. The Amlodipine component's exposure is affected by the CYP3A4 metabolic pathway: CYP3A4 inhibitors may increase Amlodipine exposure, and CYP3A4 inducers may reduce it. Alcohol is documented to have an additive hypotensive effect.

Mechanism of Action

How Coversam Works

Coversam, a combination of perindopril and amlodipine, exerts its influence through a dual-pathway action that modulates systems regulating vascular pressure and tone.

Modulating the Neurohormonal System via ACE Inhibition

This mechanism is driven by perindoprilat, the active metabolite, which competitively inhibits the Angiotensin-Converting Enzyme (ACE). By blocking this enzyme, the drug suppresses the formation of the vasoconstrictor Angiotensin II and simultaneously reduces the breakdown of the vasodilator bradykinin. This action results in balanced vasodilation (arterial and venous) and suppresses aldosterone, which influences fluid and electrolyte handling and reduces the hydraulic load on the circulation.

️ Direct Control of Arterial Smooth Muscle Tone

The second mechanism, provided by amlodipine, involves the direct blockade of L-type voltage-gated calcium channels located on the walls of the arteries. Since calcium influx is necessary for muscle contraction, blocking these channels causes the vascular smooth muscle to relax. This direct action produces peripheral arteriolar vasodilation, which decreases the Total Peripheral Resistance throughout the circulatory system, independently of hormonal regulation.

Complementary Reduction in Circulatory Resistance

The two components work together to provide a complementary, additive mechanistic effect. By influencing both the neurohormonal system and direct vascular tone, the drug engages a dual-action mechanism that influences systemic resistance across independent pathways, resulting in an overall effect profile.

Dosage and Administration Information

How Coversam is Used

Coversam (Perindopril/Amlodipine) is a Fixed-Dose Combination (FDC) medicine administered via the oral route as a tablet. Its usage is defined by high-level principles, which specify the role of this combination product in a patient's long-term therapy.


Official Administration Pattern

  • Frequency and Timing: The medicine is taken once daily as a single dose. Official usage guidance recommends administration preferably in the morning and before a meal to maintain consistent absorption. The tablet should be swallowed whole with a glass of water.

  • Role in Therapy: For many international formulations, Coversam is designated as substitution therapy. This means treatment is typically not initiated with the FDC. Instead, it is used to replace separate tablets of Perindopril and Amlodipine in patients whose blood pressure is already stable and controlled on equivalent individual component doses.


Dosing and Adjustment Principles

Coversam is available in various strengths (e.g., 5 mg/5 mg, 5 mg/10 mg, 10 mg/10 mg). The strength chosen must match the patient's existing monocomponent regimen. The US formulation (Prestalia) provides alternative standard dosing, with an initial dose of 3.5 mg/2.5 mg once daily and a maximum dose of 14 mg/10 mg.

If a dose change is required, official instructions specify that adjustment should be managed through individual titration using the separate Perindopril and Amlodipine tablets. The patient should only be switched back to a new FDC strength once the optimal dose is re-established and stable. The treatment is intended for long-term management.

Usage Constraints

An administration constraint is the instruction to avoid the consumption of grapefruit or grapefruit juice, as this can affect the bioavailability of the Amlodipine component. Furthermore, the FDC is not recommended for use in children or in patients with severe renal impairment; these groups require dose management via the individual drug components.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Coversam

The evidence landscape for Coversam (Perindopril / Amlodipine) is based on clinical research that has explored the combination for its approved indications. This overview summarizes the structure of that evidence, focusing on the types of studies conducted and the patterns observed in those studies, without offering personal advice or specific treatment expectations.


Evidence for Use in Essential Hypertension (High Blood Pressure)

The research on Coversam was studied for conditions characterized by systemic imbalance, such as high blood pressure. These studies primarily involve short-term Randomized Controlled Trials (RCTs), typically lasting less than 12 weeks. Trials were structured to compare the fixed combination pill against a placebo and against the individual ingredients alone. Researchers focused on outcomes monitoring physiological strain or stress, specifically measuring differences in Systolic and Diastolic Blood Pressure (BP). Studies also monitored the rate at which participants showed measurements related to a specific BP level.

Evidence for Use in Stable Coronary Artery Disease

Coversam was studied for conditions associated with acute or disruptive episodes, specifically those with Stable Coronary Artery Disease. For this context, the evidence is often derived from research focused on regulatory requirements, such as ensuring that taking the combination pill has the same exposure as taking the two separate pills (bioequivalence). Research also examined how the medicine was associated with certain markers of physiological strain or stress beyond blood pressure, known as Target Organ Damage (TOD).

Research Gaps and Areas of Uncertainty

While the evidence contributes to understanding short-term changes, there is limited information for long-term outcomes that look directly at the combination pill’s influence on cardiovascular morbidity and mortality. A primary limitation is that most dedicated FDC trials focused on surrogate endpoints (blood pressure, structural changes) rather than major long-term clinical events. Therefore, certainty remains low regarding the combination's direct evaluation against other treatments. Findings describe group patterns, not personal outcomes.

Frequently Asked Questions (FAQ)

Common questions about Coversam (FAQ)


Q: How quickly does Coversam start to work after I begin taking it?

Studies of the components in Coversam indicate that the active metabolite, perindoprilat, reaches its highest concentration rapidly, typically within one hour. The other component, amlodipine, reaches its highest concentration within 6 to 12 hours. The medicine is intended for long-term therapy, and the full blood pressure-lowering effect is achieved with continued daily dosing, not from a single dose.


Q: Is it normal to feel dizzy when starting Coversam?

Dizziness is listed in official regulatory documents as a Common side effect. Official safety information notes that adverse effects like dizziness and headache are more likely to occur at the beginning of the treatment as the body adjusts to the medication.


Q: Can Coversam cause a persistent dry cough?

Cough is documented as a Common adverse reaction associated with this medicine. A non-productive, dry cough is a widely known effect linked to the perindopril component, which belongs to the class of ACE inhibitors.


Q: Can Coversam affect my sleep?

Official regulatory documents list Insomnia (difficulty sleeping) as an Uncommon adverse reaction, meaning it occurs rarely. Additionally, Somnolence (drowsiness) is documented as a Common side effect, which may be more noticeable when first starting the treatment.


Q: Can Coversam make me feel tired or lethargic?

Fatigue is listed as a Common adverse reaction in the official safety documents, which patients may experience as general tiredness or a lack of energy. This effect is generally mild and may be more noticeable when first starting the treatment.


Q: What happens if I stop taking Coversam suddenly?

Coversam is indicated as a long-term therapy for chronic conditions like high blood pressure. Stopping any medication for high blood pressure abruptly without direction from your healthcare professional may result in an uncontrolled increase in blood pressure. Regarding a missed dose, official patient information generally advises never taking a double dose to make up for a missed one.


Q: What is the longest period someone has been studied taking Coversam?

Dedicated studies focusing on the fixed-dose combination often focus on short-term blood pressure outcomes. However, data from long-term, open-label studies have examined the combination's safety and efficacy over periods of up to 48 months.


Q: What is the main difference between Coversam and other blood pressure medicines?

Coversam is described as a Fixed-Dose Combination (FDC) product. The main difference is that it combines two distinct classes of medicine—an ACE inhibitor and a Calcium Channel Blocker—into a single tablet to provide a complementary dual action on the circulatory system.


Q: Why would a doctor switch me from two separate pills to Coversam?

Official documents define this FDC as substitution therapy. It is primarily used to replace the separate tablets of Perindopril and Amlodipine in patients whose blood pressure is already stable and controlled on equivalent doses, often done to simplify the patient's daily regimen and support treatment adherence.


Q: Is Coversam a maintenance drug?

Yes, this medicine is designated for the long-term management of essential hypertension (high blood pressure) and/or stable coronary artery disease. It is generally not used for initiating treatment but for maintaining control after stability has been achieved.


Q: Is Coversam prescribed for conditions other than high blood pressure?

In addition to its use for essential hypertension, Coversam is officially indicated as substitution therapy for patients with stable coronary artery disease. This means it is used in patients who have achieved stable control of both conditions using the separate components.


Q: Is it safe to drink alcohol while taking Coversam?

Official regulatory information states that alcohol may have an additive hypotensive effect, meaning it could cause an excessive drop in blood pressure when combined with this medicine. Official documents often advise caution or limitation of consumption in situations where hypotensive effects may be increased.


Q: Will Coversam cure my high blood pressure?

Coversam is described as a treatment to manage or control high blood pressure. High blood pressure is often a chronic condition requiring long-term management, and the medicine is not described in regulatory documents as a cure.


Q: Does Coversam cause weight gain?

Weight gain or weight change is not listed as a Common, Uncommon, or Very Rare adverse reaction in the official regulatory safety documents for Coversam.


Q: Does Coversam affect blood sugar levels?

The official document lists Hypoglycaemia (low blood sugar) as an Uncommon adverse reaction. This is a potential side effect associated with the perindopril (ACE inhibitor) component.


Q: Does Coversam cause muscle cramps or joint pain?

Official documents list Muscle cramps as a Common adverse reaction. Joint pain is not listed in the Common or Uncommon frequency bands.


Q: Does Coversam affect libido or sexual function?

Official documents list Impotence (erectile dysfunction) as an Uncommon adverse reaction, which is a potential side effect associated with the perindopril component.


Q: Can Coversam be used after a heart attack?

The medicine is contraindicated (prohibited) for patients with haemodynamically unstable heart failure after acute myocardial infarction. However, research involving the Perindopril component shows an association with the reduction of the risk of cardiac events in patients with stable coronary artery disease and a history of myocardial infarction.


Q: Do studies show that Coversam lowers the risk of stroke?

While the combination pill's dedicated trials focus on blood pressure, research involving the active component Perindril, studied in other trials, shows an association with a reduced risk of stroke in patients who have a history of stroke or TIA (mini-stroke).


Q: Is Coversam a generic drug or is it only available under a brand name?

Coversam is a specific brand name for the fixed-dose combination of perindopril and amlodipine. The active ingredients, perindopril and amlodipine, are widely available as individual generic medicines.


Q: Can Coversam be split or crushed?

Official usage guidance states that the tablet should be swallowed whole with a glass of water. Regulatory instructions do not permit the tablet to be split or crushed, which is important to maintain the correct function of the components.


Q: What should I do if I miss a dose of Coversam?

Official patient information generally advises taking the dose as soon as remembered unless it is nearly time for the next scheduled dose. If it is close to the next dose, the missed dose should be skipped, and the regular schedule resumed. Official patient information generally advises never taking a double dose to make up for a missed one.


Q: Does Coversam interact with herbal remedies like St. John's Wort?

The official drug label indicates that St. John's Wort is documented as an inducer of the CYP3A4 enzyme. Since the Amlodipine component of Coversam is processed by CYP3A4, co-administration may reduce the level of Amlodipine exposure in the body.


Q: How does Coversam compare to single-ingredient blood pressure drugs?

Coversam is a Fixed-Dose Combination designed to provide a complementary and additive blood pressure-lowering effect. By acting on two independent physiological pathways, it is designed to result in a more comprehensive reduction in blood pressure than using either single ingredient alone.


Q: Do I need to change my diet while taking Coversam?

Official administration instructions indicate the medicine should be taken before a meal as food can affect how the active component is absorbed, and note the need to avoid certain items. Specifically, the label instructs to avoid grapefruit or grapefruit juice, and caution is advised regarding high potassium foods or supplements.

How should Coversam be stored and disposed of?

Official Storage and Disposal Requirements for Coversam

Coversam (perindopril/amlodipine) must be stored strictly according to regulatory labeling to maintain its stability and effectiveness.

Storage Requirement Official Instruction
Temperature Store below 25 C.
Protection Keep in the original container, protected from moisture and light.
Child Safety Keep out of the sight and reach of children.
Prohibited Areas Do not store in a bathroom, near a sink, or in areas exposed to dampness or excessive heat.

Expired or unused Coversam must be disposed of responsibly. Official guidelines strictly prohibit disposal in household trash or by flushing down the toilet to protect the environment. Return the medication to a pharmacist or follow local community collection schemes for proper pharmaceutical waste management.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Coversam found in:

A-Z Index: